{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:32:00Z","timestamp":1761561120673},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1016\/j.idc.2006.01.009","type":"journal-article","created":{"date-parts":[[2007,1,13]],"date-time":"2007-01-13T19:44:10Z","timestamp":1168717450000},"page":"63-79","source":"Crossref","is-referenced-by-count":5,"title":["Assessment and Management of Chronic Hepatitis B"],"prefix":"10.1016","volume":"20","author":[{"given":"Marc G.","family":"Ghany","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward C.","family":"Doo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.idc.2006.01.009_bib1","series-title":"World Health Organization Fact Sheet\/204. Hepatitis B","year":"2000"},{"issue":"24","key":"10.1016\/j.idc.2006.01.009_bib2","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJM199712113372406","article-title":"Hepatitis B virus infection","volume":"337","author":"Lee","year":"1997","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.idc.2006.01.009_bib3","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/hep.1840080527","article-title":"A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children","volume":"8","author":"Lok","year":"1988","journal-title":"Hepatology"},{"issue":"5415","key":"10.1016\/j.idc.2006.01.009_bib4","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1126\/science.284.5415.825","article-title":"Viral clearance without destruction of infected cells during acute HBV infection","volume":"284","author":"Guidotti","year":"1999","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.idc.2006.01.009_bib5","doi-asserted-by":"crossref","first-page":"744","DOI":"10.7326\/0003-4819-94-6-744","article-title":"Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis","volume":"94","author":"Hoofnagle","year":"1981","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.idc.2006.01.009_bib6","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/0016-5085(87)90250-2","article-title":"Hepatitis B virus deoxyribonucleic acid in liver of chronic carriers. Correlation with serum markers and changes associated with loss of hepatitis B e antigen after antiviral therapy","volume":"93","author":"Di Bisceglie","year":"1987","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.idc.2006.01.009_bib7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0016-5085(80)90130-4","article-title":"Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection","volume":"79","author":"Realdi","year":"1980","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.idc.2006.01.009_bib8","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7326\/0003-4819-118-3-199302010-00006","article-title":"The natural history of asymptomatic hepatitis B surface antigen carriers","volume":"118","author":"de Franchis","year":"1993","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.idc.2006.01.009_bib9","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/0016-5085(92)91188-A","article-title":"Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver","volume":"103","author":"de Jongh","year":"1992","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.idc.2006.01.009_bib10","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/hep.1840070424","article-title":"Chronic type B hepatitis and the healthy HBsAg carrier state","volume":"7","author":"Hoofnagle","year":"1987","journal-title":"Hepatology"},{"key":"10.1016\/j.idc.2006.01.009_bib11","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1053\/jhep.2001.27834","article-title":"Hepatitis B e antigen-negative chronic hepatitis B","volume":"34","author":"Hadziyannis","year":"2001","journal-title":"Hepatology"},{"issue":"8663","key":"10.1016\/j.idc.2006.01.009_bib12","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S0140-6736(89)90713-7","article-title":"Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection","volume":"2","author":"Carman","year":"1989","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.idc.2006.01.009_bib13","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/0168-8278(90)90062-V","article-title":"A new hepatitis B virus strain in patients with severe anti-HBe-positive chronic hepatitis B","volume":"10","author":"Brunetto","year":"1990","journal-title":"J Hepatol"},{"key":"10.1016\/j.idc.2006.01.009_bib14","first-page":"7","article-title":"Hepatitis B e antigen-negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment","volume":"1","author":"Hadziyannis","year":"1995","journal-title":"Viral Hepatitis Review"},{"issue":"6","key":"10.1016\/j.idc.2006.01.009_bib15","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1053\/jhep.2002.33638","article-title":"Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B","volume":"35","author":"Hsu","year":"2002","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.idc.2006.01.009_bib16","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/gast.2001.24839","article-title":"Management of hepatitis B: 2000\u2014summary of a workshop","volume":"120","author":"Lok","year":"2001","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.idc.2006.01.009_bib17","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0168-8278(03)00083-7","article-title":"EASL International Consensus Conference on Hepatitis B. 13\u201314 September, 2002: Geneva, Switzerland. Consensus statement","volume":"38","year":"2003","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.idc.2006.01.009_bib18","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1053\/jhep.2001.29401","article-title":"Practice Guidelines Committee, American Association for the Study of Liver Diseases. Chronic hepatitis B","volume":"34","author":"Lok","year":"2001","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.idc.2006.01.009_bib19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1542-3565(03)00312-4","article-title":"A treatment algorithm for the management of chronic hepatitis B virus infection in the United States","volume":"2","author":"Keeffe","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.idc.2006.01.009_bib20","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1099\/0022-1317-69-10-2575","article-title":"Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes","volume":"69","author":"Okamoto","year":"1988","journal-title":"J Gen Virol"},{"issue":"2","key":"10.1016\/j.idc.2006.01.009_bib21","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1006\/viro.1994.1060","article-title":"Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes","volume":"198","author":"Norder","year":"1994","journal-title":"Virology"},{"issue":"Pt 1","key":"10.1016\/j.idc.2006.01.009_bib22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1099\/0022-1317-81-1-67","article-title":"A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness","volume":"81","author":"Stuyver","year":"2000","journal-title":"J Gen Virol"},{"issue":"2","key":"10.1016\/j.idc.2006.01.009_bib23","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0016-5085(03)00895-3","article-title":"Hepatitis B virus genotypes in the United States: results of a nationwide study","volume":"125","author":"Chu","year":"2003","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.idc.2006.01.009_bib24","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1086\/314688","article-title":"Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers","volume":"179","author":"Lindh","year":"1999","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2006.01.009_bib25","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1053\/gast.2002.33588","article-title":"Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C","volume":"122","author":"Chu","year":"2002","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.idc.2006.01.009_bib26","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1053\/jhep.2001.20532","article-title":"Acase-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group","volume":"33","author":"Orito","year":"2001","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.idc.2006.01.009_bib27","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0016-5085(00)70261-7","article-title":"Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B","volume":"118","author":"Kao","year":"2000","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.idc.2006.01.009_bib28","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1440-1746.2002.02605.x","article-title":"Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent","volume":"17","author":"Thakur","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.idc.2006.01.009_bib29","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/hep.1840220605","article-title":"Hepatitis B virus infection: precore mutants and its relation to viral genotypes and core mutations","volume":"22","author":"Rodriguez-Frias","year":"1995","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.idc.2006.01.009_bib30","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0168-8278(00)80135-X","article-title":"Hepatitis B genotypes and the response to interferon therapy","volume":"33","author":"Kao","year":"2000","journal-title":"J Hepatol"},{"issue":"9454","key":"10.1016\/j.idc.2006.01.009_bib31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trail","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"issue":"9260","key":"10.1016\/j.idc.2006.01.009_bib32","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S0140-6736(00)04219-7","article-title":"20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw","volume":"357","author":"Zollner","year":"2001","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.idc.2006.01.009_bib33","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1053\/jhep.2003.50458","article-title":"Determinants for sustained HBeAg response to lamivudine therapy","volume":"38","author":"Chien","year":"2003","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.idc.2006.01.009_bib34","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0016-5085(03)00700-5","article-title":"Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1","volume":"125","author":"Westland","year":"2003","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.idc.2006.01.009_bib35","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.idc.2006.01.009_bib36","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1053\/jhep.2000.17914","article-title":"Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study","volume":"32","author":"McMahon","year":"2000","journal-title":"Hepatology"},{"issue":"13","key":"10.1016\/j.idc.2006.01.009_bib37","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/jnci\/83.13.916","article-title":"Workshop on screening for hepatocellular carcinoma","volume":"83","author":"McMahon","year":"1991","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.idc.2006.01.009_bib38","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/gut.52.3.420","article-title":"Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase","volume":"52","author":"van Nunen","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.idc.2006.01.009_bib39","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1053\/jhep.2000.16665","article-title":"Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea","volume":"32","author":"Song","year":"2000","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.idc.2006.01.009_bib40","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1053\/jhep.2003.50117","article-title":"Durability of serologic response after lamivudine treatment of chronic hepatitis B","volume":"37","author":"Dienstag","year":"2003","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.idc.2006.01.009_bib41","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1365-2893.2000.00192.x","article-title":"Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture","volume":"7","author":"Ying","year":"2000","journal-title":"J Viral Hepat"},{"issue":"1","key":"10.1016\/j.idc.2006.01.009_bib42","doi-asserted-by":"crossref","first-page":"F7","DOI":"10.1097\/00002030-200301030-00002","article-title":"An open-label study of tenofovir in HIV-1 and Hepatitis B virus coinfected individuals","volume":"17","author":"Nelson","year":"2003","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.idc.2006.01.009_bib43","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1046\/j.1365-2893.2000.00210.x","article-title":"Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir","volume":"7","author":"Ying","year":"2000","journal-title":"J Viral Hepat"},{"issue":"2","key":"10.1016\/j.idc.2006.01.009_bib44","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1056\/NEJM200301093480218","article-title":"Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus","volume":"348","author":"Benhamou","year":"2003","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.idc.2006.01.009_bib45","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/00002030-200303280-00028","article-title":"Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus e-minus patients with YMDD mutations after 4 weeks of tenofovir therapy","volume":"17","author":"Bruno","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2006.01.009_bib46","first-page":"A1199","article-title":"A preliminary study of lobucavir for chronic hepatitis B","volume":"26","author":"Bloomer","year":"1997","journal-title":"Hepatology"},{"issue":"19","key":"10.1016\/j.idc.2006.01.009_bib47","doi-asserted-by":"crossref","first-page":"8495","DOI":"10.1073\/pnas.88.19.8495","article-title":"Inhibition of the replication of hepatitis B virus in vitro by 2\u2032,3\u2032-dideoxy-3\u2032-thiacytidine and related analogues","volume":"88","author":"Doong","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.idc.2006.01.009_bib48","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1128\/AAC.44.6.1757-1760.2000","article-title":"Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks","volume":"44","author":"Korba","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.idc.2006.01.009_bib49","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1128\/AAC.46.6.1734-1740.2002","article-title":"Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection","volume":"46","author":"Gish","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2006.01.009_bib50","unstructured":"Shiffman ML, et al. AASLD 2004 [abstract 22]."},{"key":"10.1016\/j.idc.2006.01.009_bib51","unstructured":"Gish. AASLD 2002 [abstract 838]."},{"issue":"Suppl 3","key":"10.1016\/j.idc.2006.01.009_bib52","first-page":"113","article-title":"Preclinical investigation of L-FMAU as an antihepatitis B virus agent","volume":"3","author":"Chu","year":"1998","journal-title":"Antivir Ther"},{"issue":"1","key":"10.1016\/j.idc.2006.01.009_bib53","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1128\/JVI.75.1.311-322.2001","article-title":"Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis","volume":"75","author":"Zhu","year":"2001","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.idc.2006.01.009_bib54","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00042560-200201010-00002","article-title":"Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails","volume":"29","author":"Mewshaw","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"10.1016\/j.idc.2006.01.009_bib55","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1053\/jhep.2002.35070","article-title":"Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses","volume":"36","author":"Seigneres","year":"2002","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2006.01.009_bib56","first-page":"119","article-title":"Antiviral beta-L-nucleosides specific for hepatitis B virus infection","volume":"12","author":"Standring","year":"2001","journal-title":"Antivir Chem Chemother"},{"issue":"4","key":"10.1016\/j.idc.2006.01.009_bib57","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1053\/gast.2001.22454","article-title":"Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection","volume":"120","author":"Doo","year":"2001","journal-title":"Gastroenterology"},{"issue":"5608","key":"10.1016\/j.idc.2006.01.009_bib58","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1126\/science.1077215","article-title":"Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids","volume":"299","author":"Deres","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.idc.2006.01.009_bib59","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/S0264-410X(00)00461-8","article-title":"Immunotherapy of chronic hepatitis B by anti-HBV vaccine: from present to future","volume":"19","author":"Michel","year":"2001","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.idc.2006.01.009_bib60","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1053\/jhep.2003.50146","article-title":"Inhibition of hepatitis B virus expression and replication by RNA interference","volume":"37","author":"Shlomai","year":"2003","journal-title":"Hepatology"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552006000122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552006000122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T18:52:04Z","timestamp":1587322324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552006000122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["S0891552006000122"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2006.01.009","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2006,3]]}}}